{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T13:10:37Z","timestamp":1736169037415,"version":"3.32.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"DOI":"10.7759\/cureus.76996","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:41:13Z","timestamp":1736167273000},"source":"Crossref","is-referenced-by-count":0,"title":["Calciphylaxis: Beating the Odds"],"prefix":"10.7759","author":[{"given":"Jos\u00e9 M\u00e1rio","family":"Bastos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Oliveira Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Joao","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcy234","article-title":"Review: update on the management of calciphylaxis","volume":"112","author":"Seethapathy H","year":"2019","unstructured":"Seethapathy H, Brandenburg VM, Sinha S, El-Azhary RA, Nigwekar SU. Review: update on the management of calciphylaxis. QJM. 2019, 112:29-34. 10.1093\/qjmed\/hcy234","journal-title":"QJM"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.065","article-title":"Calciphylaxis: natural history, risk factor analysis, and outcome","volume":"56","author":"Weenig RH","year":"2007","unstructured":"Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007, 56:569-79. 10.1016\/j.jaad.2006.08.065","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2010.00738.x","article-title":"Sodium thiosulfate: new hope for the treatment of calciphylaxis","volume":"23","author":"Hayden MR","year":"2010","unstructured":"Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial. 2010, 23:258-62. 10.1111\/j.1525-139X.2010.00738.x","journal-title":"Semin Dial"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015091065","article-title":"A nationally representative study of calcific uremic arteriolopathy risk factors","volume":"27","author":"Nigwekar SU","year":"2016","unstructured":"Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, Chan KE. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016, 27:3421-9. 10.1681\/ASN.2015091065","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505292","article-title":"Calciphylaxis","volume":"378","author":"Nigwekar SU","year":"2018","unstructured":"Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018, 378:1704-14. 10.1056\/NEJMra1505292","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.366","article-title":"Warfarin-related nephropathy and vascular calcification: clinical relevance","volume":"85","author":"Brandenburg VM","year":"2014","unstructured":"Brandenburg VM, Kramann R, Rothe H, et al.. Warfarin-related nephropathy and vascular calcification: clinical relevance. Kidney Int. 2014, 85:1006-14. 10.1038\/ki.2013.366","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01722-y","article-title":"Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study","volume":"21","author":"Gaisne R","year":"2020","unstructured":"Gaisne R, P\u00e9r\u00e9 M, Menoyo V, Hourmant M, Larmet-Burgeot D. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol. 2020, 21:63. 10.1186\/s12882-020-01722-y","journal-title":"BMC Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17305.x","article-title":"How can the poor outcomes for diabetic dialysis patients be improved?","volume":"17","author":"Wyne K","year":"2004","unstructured":"Wyne K. How can the poor outcomes for diabetic dialysis patients be improved?. Semin Dial. 2004, 17:194-5. 10.1111\/j.0894-0959.2004.17305.x","journal-title":"Semin Dial"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz155","article-title":"Effects of a medium cut-off (Theranova(\u00ae)) dialyser on haemodialysis patients: a prospective, cross-over study","volume":"14","author":"Cozzolino M","year":"2021","unstructured":"Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A. Effects of a medium cut-off (Theranova(\u00ae)) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2021, 14:382-9. 10.1093\/ckj\/sfz155","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15034","article-title":"Treatments for disease damage in cutaneous lupus erythematosus: a narrative review","volume":"34","author":"Joseph AK","year":"2021","unstructured":"Joseph AK, Abbas LF, Chong BF. Treatments for disease damage in cutaneous lupus erythematosus: a narrative review. Dermatol Ther. 2021, 34:e15034. 10.1111\/dth.15034","journal-title":"Dermatol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00803.x","article-title":"Risk factors and mortality associated with calciphylaxis in end-stage renal disease","volume":"60","author":"Mazhar AR","year":"2001","unstructured":"Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001, 60:324-32. 10.1046\/j.1523-1755.2001.00803.x","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2256413","article-title":"Multimodality approach to treat calciphylaxis in end-stage kidney disease patients","volume":"45","author":"Lajoie C","year":"2023","unstructured":"Lajoie C, Ghanemi A, Bourbeau K, Sidib\u00e9 A, Wang YP, Desmeules S, Mac-Way F. Multimodality approach to treat calciphylaxis in end-stage kidney disease patients. Ren Fail. 2023, 45:2256413. 10.1080\/0886022X.2023.2256413","journal-title":"Ren Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/328132-calciphylaxis-beating-the-odds","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:41:14Z","timestamp":1736167274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/328132-calciphylaxis-beating-the-odds"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.76996","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}